@CaribouBio Caribou Biosciences

Caribou Biosciences posts on X about $crbu, ceo, cart, we are the most. They currently have [-----] followers and [---] posts still getting attention that total [---] engagements in the last [--] hours.

Engagements: [---] #

• [--] Week [-----] -15%
• [--] Months [------] +203%
• [--] Year [------] +385%

Mentions: [--] #

• [--] Months [--] +57%
• [--] Year [--] +200%

Followers: [-----] #

• [--] Week [-----] +0.09%
• [--] Months [-----] +0.93%
• [--] Year [-----] +0.95%

CreatorRank: [---------] #

Social Influence

Social category influence stocks 96.67% finance 5% countries 2.5% travel destinations 1.67% financial services 0.83% exchanges 0.83% technology brands 0.83%

Social topic influence $crbu #5, ceo 21.67%, cart #344, we are 17.5%, phd 15%, in the 12.5%, to the 5%, poster 5%, future 5%, the first 4.17%

Top accounts mentioned or mentioned by @yaireinhorn @sfbusinesstimes @dadbodfamilyguy @genbio @biomedicalrx @jefferies @astct @citi @forbes @aacr @halevymike @ahenryokc @bloodcancerutds @leerinkpartners @biocoms @bloombergs @citis @incs @forbesunder30 @bradloncar

Top assets mentioned Caribou Biosciences, Inc. (CRBU) AbbVie Inc (ABBV)

Top Social Posts

Top posts by engagements in the last [--] hours

"Keep an eye out for the Herd at #ASH22 as several members of our clinical medical affairs and leadership teams will be on site Grab them and ask about our clinical-stage allogeneic CAR-T cell therapies. #lymphoma #multiplemyeloma #ASH2022"
X Link 2022-12-10T14:39Z [----] followers, [--] engagements

"Caribou is uniquely positioned in H1 [----] with two clinical data milestones anticipated as we rapidly advance our off-the-shelf CAR-T cell therapies. Read our fourth quarter and full year [----] financial results and business update: $CRBU https://bit.ly/3Fk5GSQ https://bit.ly/3Fk5GSQ"
X Link 2025-03-10T20:08Z [----] followers, [----] engagements

"Caption: Caribou continues to see encouraging data from lead clinical programs in oncology CB-010 for 2L LBCL and CB-011 for r/r #multiplemyeloma and has taken actions to prioritize allocation of resources for these two Phase [--] clinical programs. $CRBU https://investor.cariboubio.com/news-releases/news-release-details/caribou-biosciences-announces-strategic-pipeline-prioritization https://investor.cariboubio.com/news-releases/news-release-details/caribou-biosciences-announces-strategic-pipeline-prioritization"
X Link 2025-04-24T20:16Z [----] followers, 11.2K engagements

"Tune into the webcast with Rachel Haurwitz PhD at BofA Securities [----] Health Care Conference. Read here for more details: $CRBU https://bit.ly/4iUFw7o https://bit.ly/4iUFw7o"
X Link 2025-05-06T21:00Z [----] followers, [----] engagements

"Were headed to the @Jefferies Global Healthcare Conference next week for a fireside chat. Learn more: https://bit.ly/4dBIexv https://bit.ly/4dBIexv"
X Link 2025-05-28T20:03Z [----] followers, [----] engagements

"Tune in to a fireside chat tomorrow with our president and CEO Rachel Haurwitz PhD at the @Jefferies Global Healthcare Conference. Tune into the webcast here: #CellTherapy #CRISPR $CRBU https://bit.ly/4jPJm2d https://bit.ly/4jPJm2d"
X Link 2025-06-03T13:00Z [----] followers, [----] engagements

"Caribou Biosciences is heading to #IMS2025. We are leading the way for multiple myeloma treatment by advancing CB-011 an allogeneic CAR-T cell therapy designed to be scalable off-the-shelf and accessible. #Myeloma #CellTherapy $CRBU"
X Link 2025-09-12T13:16Z [----] followers, [----] engagements

"Mark your calendars as our team heads to two upcoming investor conferences. Learn #CRISPR $CRBU https://bit.ly/496gMI9 https://bit.ly/496gMI9"
X Link 2025-11-03T22:31Z [----] followers, [----] engagements

"Patients who live [--] hours from treatment centers are 40% less likely to receive CAR-T cell therapy. Register for webcast at the ASH Annual Meeting with leading community and academic clinicians to discuss access: #CellTherapy #CRISPR $CRBU #ASH25 https://bit.ly/4prwodV https://bit.ly/4prwodV"
X Link 2025-11-25T20:39Z [----] followers, [----] engagements

"Were excited to host our KOL event during #ASH25 to discuss how vispa-cel can broaden access for patients with second-line large B cell lymphoma including through use in the community setting. Register today: #CellTherapy #CRISPR $CRBU https://bit.ly/3KzpDrK https://bit.ly/3KzpDrK"
X Link 2025-12-01T21:06Z [----] followers, [----] engagements

"STARTING SOON: Dont miss the KOL panel at #ASH25 as physicians from community & academic centers discuss opportunities for expanding treatment access with vispa-cel an allogeneic CAR-T cell therapy. Tune into the webcast here: #CellTherapy #CRISPR $CRBU https://bit.ly/4oC0Zog https://bit.ly/4oC0Zog"
X Link 2025-12-06T12:00Z [----] followers, [----] engagements

"This New Year we are more dedicated than ever to deliver on the promise of off-the-shelf cell therapies offering rapid treatment scalable manufacturing and the possibility of broad patient access by bringing these transformative treatments closer to where patients live. 💙🧬"
X Link 2026-01-01T17:27Z [----] followers, [----] engagements

"Join $CRBU tomorrow morning as the company shares data from the ANTLER and CaMMouflage phase [--] clinical trials. Conference call and webcast to be hosted at 8:00am ET. Link to webcast here: https://bit.ly/4oQHXv3 https://bit.ly/4oQHXv3"
X Link 2025-11-02T21:01Z [----] followers, [----] engagements

"We are excited to share the first clinical data from the Phase [--] CaMMouflage trial of CB-011 in patients with multiple myeloma showing deep durable responses with a manageable safety profile. 🔗 Webcast at 8:00 am ET here: https://bit.ly/4ojiwCi https://bit.ly/4ojiwCi"
X Link 2025-11-03T12:01Z [----] followers, [----] engagements

"We are excited to share data from the ANTLER trial showing that vispa-cel (CB-010) an allogeneic CAR-T cell therapy for patients with non-Hodgkin lymphoma drives deep and durable responses on par with the autologous CAR-Ts. 🔗Join webcast at 8:00 am ET: https://bit.ly/3JDgVIt https://bit.ly/3JDgVIt"
X Link 2025-11-03T12:04Z [----] followers, [----] engagements

"Today we reported our Q3 earnings. Learn more in our third quarter [----] financial results and business update here: #CRISPR #CellTherapy $CRBU https://bit.ly/4hXhhq1 https://bit.ly/4hXhhq1"
X Link 2025-11-12T21:08Z [----] followers, [----] engagements

"Happy New Year from all of us at Caribou As we turn the page to [----] we do so with deep hope for the patients we aim to serve through our allogeneic CAR-T cell therapies. Heres to a year of bold science compassionate care and transformative progress.💙🧬 #CRISPR #CellTherapy"
X Link 2026-01-01T14:00Z [----] followers, [----] engagements

"Dont miss @BloodCancerUtds Therapy Acceleration Program annual expert panel including our CMO Tina Albertson MD PhD. Register here: #CellTherapy #CRISPR $CRBU https://na.eventscloud.com/website/91404/ https://na.eventscloud.com/website/91404/"
X Link 2026-01-16T21:22Z [----] followers, [----] engagements

"Caribou will be at @ASTCT presenting translational data for the ANTLER and CaMMouflage allogenic CAR-T cell therapy clinical trials. Read more here: #CellTherapy #CRISPR $CRBU https://bit.ly/4qlbAFc https://bit.ly/4qlbAFc"
X Link 2026-02-04T13:04Z [----] followers, [----] engagements

"If youre in San Diego for #AdvancedTherapiesWeek dont miss talks from Justin Skoble PhD Caribous vice president of technical operations. See you there #CellTherapy #CRISPR $CRBU"
X Link 2026-02-09T20:33Z [----] followers, [---] engagements

"Well be attending the @Citi [----] Virtual Oncology Leadership Summit and @LeerinkPartners Global Healthcare Conference in the coming weeks. Learn more: #CellTherapy #CRISPR $CRBU https://bit.ly/4qCWXNJ https://bit.ly/4qCWXNJ"
X Link 2026-02-12T21:07Z [----] followers, [---] engagements

"We're excited to share that our president and CEO Rachel Haurwitz was named as one of @biocom's ten Annual Catalyst Award winners recognizing leaders under [--] making an impact on CA's life science industry Read more here: http://bit.ly/2mely0E http://bit.ly/2mely0E"
X Link 2019-09-24T02:34Z [----] followers, [--] engagements

"🎉 Congratulations to our President and CEO Rachel Haurwitz on being named to the inaugural class of @Bloombergs New Economy Catalysts amongst innovators focused on accelerating solutions. Learn about the #BloombergCatalysts & upcoming live event: https://bit.ly/3v8RW2H https://bit.ly/3v8RW2H"
X Link 2021-06-09T22:57Z [----] followers, [--] engagements

"Next week our CEO Rachel Haurwitz PhD will participate in a panel discussion on Exploring the State of Play in Cell Therapy at @Citis 16th Annual BioPharma Conference. Catch the live webcast Sept [--] at 10:40am ET or by archive for [--] days: https://bit.ly/3BxkmGY https://bit.ly/3BxkmGY"
X Link 2021-09-01T12:06Z [----] followers, [--] engagements

"Delighted to welcome Ran Zheng as the newest member of our board of directors. She brings 25+ years of biotechnology industry leadership experience in biologics drug development with broad expertise in technical operations and manufacturing. Learn more: http://bit.ly/3kSDtFZ http://bit.ly/3kSDtFZ"
X Link 2021-09-29T21:07Z [----] followers, [--] engagements

"Our CEO Rachel Haurwitz PhD will be presenting a corporate update at the 40th Annual J.P. Morgan Healthcare Conference on Thursday January [--] [----] at 9:45 am ET. Catch the live webcast or view in our archive for [--] days: #JPM22 https://bit.ly/3FEs6Jk https://bit.ly/3FEs6Jk"
X Link 2022-01-04T21:07Z [----] followers, [--] engagements

"We are pleased to welcome Syed Rizvi MD as our Chief Medical Officer. Dr. Rizvi brings [--] years of experience in all stages of drug development supporting approval & commercialization of autologous CAR-T cell cancer treatments. #WelcometotheHerd https://bit.ly/3nE0xt5 https://bit.ly/3nE0xt5"
X Link 2022-01-18T13:05Z [----] followers, [--] engagements

"As we kick off #WomensHistoryMonth we are so pleased to see our CEO Rachel Haurwitz PhD featured in the @SFBusinessTimes series on Women Who Lead. We are committed to growing and fostering female presence in #STEM education and careers. Learn more: https://www.bizjournals.com/sanfrancisco/news/2022/03/04/crispr-jennifer-doudna-women.html https://www.bizjournals.com/sanfrancisco/news/2022/03/04/crispr-jennifer-doudna-women.html"
X Link 2022-03-04T22:41Z [----] followers, [--] engagements

"Our CEO Rachel Haurwitz PhD delivered a keynote today on using #CRISPR-based editing for off-the-shelf immune cell therapies for hematologic and solid tumors at the #IO360 Summit"
X Link 2022-03-17T14:09Z [----] followers, [--] engagements

"Were celebrating [--] years of Caribou Biosciences In the last decade we developed the chRDNA genome-editing platform and today we are advancing our pipeline of off-the-shelf CAR-T and CAR-NK #celltherapies. Stay tuned. This is just the beginning for Caribou"
X Link 2022-07-28T15:48Z [----] followers, [--] engagements

"We could not be prouder that our President & CEO Rachel Haurwitz Ph.D. was named one of @SFBusinessTimes [----] Most Admired CEOs Congratulations Rachel You continue to motivate and inspire #TheHerd to make a difference in patients lives. #SFBT #MostAdmiredCEOs #HerdImpact"
X Link 2022-11-10T15:53Z [----] followers, [--] engagements

"Thrilled our co-founder Dr. Doudna received the [----] Japan Prize for outstanding & original achievements #CRISPR https://goo.gl/K87L2q https://goo.gl/K87L2q"
X Link 2017-02-02T18:11Z [----] followers, [--] engagements

"In recognition of #InternationalWomensDay were delighted to share our CEO Rachel Haurwitzs well-deserved spot in the @SFBusinessTimes feature: Women Who Lead in Life Sciences. #iwd2018 https://www.bizjournals.com/sanfrancisco/c/women-who-lead-in-life-sciences-2018/2942/rachel-haurwitz.html https://www.bizjournals.com/sanfrancisco/c/women-who-lead-in-life-sciences-2018/2942/rachel-haurwitz.html"
X Link 2018-03-08T21:31Z [----] followers, [--] engagements

"Our CEO Rachel Haurwitz and Caribou co-founder Jennifer Doudna have been featured amongst #female business leaders on @Incs first #FemaleFounders [---] list and we could not be more proud Check out the full list here: https://www.inc.com/magazine/201810/inc-staff/christina-tosi-and-other-visionaries-female-founders-100.html https://www.inc.com/magazine/201810/inc-staff/christina-tosi-and-other-visionaries-female-founders-100.html"
X Link 2018-10-04T17:01Z [----] followers, [--] engagements

"We're excited to share that @Forbes recognized our CEO Rachel Haurwitz and Caribou co-founder Jennifer Doudna among top female #tech leaders on their [----] America's Top [--] Women in Tech list Check it out here: https://bit.ly/2DTA84z https://bit.ly/2DTA84z"
X Link 2018-12-04T14:42Z [----] followers, [--] engagements

"Were excited to share Caribous new website Check it out here: https://www.cariboubio.com/ https://www.cariboubio.com/"
X Link 2021-05-10T20:10Z [----] followers, [--] engagements

"Pleased to welcome Nancy Whiting as the newest member of our board of directors. Dr. Whiting brings over [--] years of biotechnology industry expertise in drug and portfolio development as well as significant strategic leadership experience. Learn more: https://bit.ly/38cuzfp https://bit.ly/38cuzfp"
X Link 2021-08-25T20:03Z [----] followers, [--] engagements

"This summer we had the pleasure of celebrating our ninth birthday. Were thankful to have such talented and dedicated team members working to make a difference in the lives of patients. Cant wait to see where this team will take us in the next nine years"
X Link 2021-09-15T15:17Z [----] followers, [--] engagements

"Today our CEO Rachel Haurwitz PhD is participating at the Chardan Virtual 5th Annual Genetic Medicines Conference discussing gene editing & next-generation technologies. Catch the live webcast on Oct [--] at 5pm ET or by archive for [--] days: https://bit.ly/3uMGBGY https://bit.ly/3uMGBGY"
X Link 2021-10-04T16:33Z [----] followers, [--] engagements

"We are honored to share that our CEO Rachel Haurwitz PhD was selected as an all-time all-star in @ForbesUnder30 Hall of Fame 10th anniversary issue. Check out her feature along with the other incredible individuals who were selected: #ForbesUnder30 https://bit.ly/3mRC9nq https://bit.ly/3mRC9nq"
X Link 2022-01-05T20:03Z [----] followers, [--] engagements

"#DYK women make up 29% of the #STEM labor force Women make up 55% of our team [--] of [--] BOD & [--] of [--] executives on our leadership team are female. We are challenging the gender norms to #BreakTheBias for women in our schools communities & workplaces. #InternationalWomensDay"
X Link 2022-03-08T17:33Z [----] followers, [--] engagements

"Thanks @bradloncar for the chat on Caribou and what weve been up to Talking allo CAR-T with Rachel Haurwitz of Caribou Biosciences. We discuss PD-1 knockout cloaking and the recent CRISPR patent ruling. #IO360NYC https://t.co/qxsYG0H0nB Talking allo CAR-T with Rachel Haurwitz of Caribou Biosciences. We discuss PD-1 knockout cloaking and the recent CRISPR patent ruling. #IO360NYC https://t.co/qxsYG0H0nB"
X Link 2022-03-21T18:03Z [----] followers, [--] engagements

"Paul Donohoue our Platform Discovery Group Lead will present tomorrow on versatile chRDNA editing for engineering immune and #stemcells at FASEBs Genome Engineering Conference in Lisbon Portugal. #GECSRC22"
X Link 2022-06-27T21:43Z [----] followers, [--] engagements

"Caribou is proud to be advancing allogeneic cell therapies that may help #CancelBloodCancer. This month well #TurnItRed in honor of those impacted by #BloodCancers. #BloodCancerAwarenessMonth #FightBloodCancer"
X Link 2022-09-01T16:15Z [----] followers, [--] engagements

"We are thrilled to receive #RMAT and Fast Track designations from the #FDA for CB-010 an off-the-shelf anti-CD19 #CARTcelltherapy More details here: $CRBU https://investor.cariboubio.com/news-releases/news-release-details/caribou-biosciences-announces-fda-granted-regenerative-medicine https://investor.cariboubio.com/news-releases/news-release-details/caribou-biosciences-announces-fda-granted-regenerative-medicine"
X Link 2022-11-29T14:03Z [----] followers, [--] engagements

"Don't miss the fireside chat tomorrow with our president and CEO Rachel Haurwitz PhD at the @Citi Biopharma Back to School Conference. Tune into the webcast here: #CellTherapy #CRISPR $CRBU https://bit.ly/47pLsmG https://bit.ly/47pLsmG"
X Link 2025-09-02T16:20Z [----] followers, [----] engagements

"Thank you @techreview for including our CEO Rachel Haurwitz on your [----] [--] Innovators Under [--] list #TR35 #CRISPR https://www.technologyreview.com/lists/innovators-under-35/2017/entrepreneur/rachel-haurwitz/ https://www.technologyreview.com/lists/innovators-under-35/2017/entrepreneur/rachel-haurwitz/"
X Link 2017-08-16T15:50Z [----] followers, [--] engagements

"In its Rising Stars series @ozy featured our CEO Rachel Haurwitz as someone set to change #medicine #agriculture & #biotechnology. Learn more about her journey from researcher to CEO & how Caribou is using #CRISPR to fight #cancer & more https://www.ozy.com/rising-stars/this-scientist-turned-ceo-wants-to-gene-edit-a-way-to-cure-cancer/85243 https://www.ozy.com/rising-stars/this-scientist-turned-ceo-wants-to-gene-edit-a-way-to-cure-cancer/85243"
X Link 2018-03-19T13:35Z [----] followers, [--] engagements

"Unbelievably proud of our co-founder Jennifer Doudna and colleague @e__charpentier for winning the @NobelPrize in #Chemistry for their cutting-edge development of the CRISPR-Cas9 #geneticediting method. Read more about the exciting news here: https://bit.ly/3lmZhHd https://bit.ly/3lmZhHd"
X Link 2020-10-07T20:41Z [----] followers, [--] engagements

"Excited to share that Caribou is now publicly listed on @nasdaq as $CRBU We look forward to progressing our scientific innovations in chRDNA-edited allogeneic cell therapies to transform the lives of patients living with devastating diseases"
X Link 2021-07-23T15:24Z [----] followers, [--] engagements

"Excited to announce publication of our data in @molecularcell demonstrating high specificity genome editing w/our proprietary #chRDNA technology reinforcing our commitment to develop unique allogeneic CAR-T cell therapies for hematologic malignancies. https://bit.ly/3n5q7rk https://bit.ly/3n5q7rk"
X Link 2021-09-02T22:20Z [----] followers, [--] engagements

"Paul Donohoue our Platform Discovery Group Lead will present a poster on Caribous chRDNA platform today at the American Society of Gene & Cell Therapys 25th Annual Meeting. #ASGCT22"
X Link 2022-05-16T18:50Z [----] followers, [--] engagements

"Were excited to announce the U.S. #FDA has cleared our IND application for CB-011 our anti-BCMA #CARTcelltherapy with immune cloaking for r/r #multiplemyeloma and we look forward to initiating patient enrollment for the CaMMouflage trial in early [----]. http://bit.ly/3XirT8h http://bit.ly/3XirT8h"
X Link 2022-11-21T14:16Z [----] followers, [--] engagements

"Our next-generation chRDNA genome-editing technology is the foundation for the development of differentiated allogeneic cell therapies. Learn more about chRDNA and our other technologies on our website #CRISPR #CellTherapies https://www.cariboubio.com/technology/ https://www.cariboubio.com/technology/"
X Link 2023-07-20T14:30Z [----] followers, [----] engagements

"Our clinical and medical affairs teams will be attending the [----] Lymphoma Leukemia & Myeloma Congress in New York City next week. We hope to see you there Head to the #LLM23 website for more details: #lymphoma #leukemia #myeloma https://bit.ly/46gTXfZ The Accredited Education You're Looking For Is Here. Did you know The #LLMCongress2023 has created acustomizable agendato meet the educational needs of all hematologist-oncologist. Choose from16 educational sessionseach with its own unique highlights. Which Tracks Will https://t.co/k4OJHMT4rx https://bit.ly/46gTXfZ The Accredited Education"
X Link 2023-10-11T15:59Z [----] followers, [----] engagements

"Join us in congratulating Paul Donohoue Caribou's associate director of platform discovery for his selection as a Biocom California [----] Life Science Catalyst Award winner Congratulations and incredibly well-deserved #CRISPR We are pleased to announce this year's annual Life Science Catalyst Award recipients. 🏆 Join us in congratulating all [--] winners recognized for exceptional achievement and leadership in the California life science industry before the age of [--]. Read more: https://t.co/gv21Q30n36 https://t.co/wNwjZkN8s3 We are pleased to announce this year's annual Life Science Catalyst"
X Link 2023-11-01T19:42Z [----] followers, [----] engagements

"Reporting from #ASH23 day [--] we had an amazing start to this years meeting and look forward to speaking with even more of you tomorrow at booth number #2251 #CRISPR #CARTcelltherapy #hematology #myeloma #lymphoma @ASH_hematology"
X Link 2023-12-10T06:35Z [----] followers, [----] engagements

"We know why Paul Donohoue was instrumental in making Caribou what it is today but do you Paul recounts the invention of chRDNA genome editing with @medicine_maker in this months issue. Read the full piece here: https://bit.ly/48pCLGM https://bit.ly/48pCLGM"
X Link 2024-01-09T19:57Z [----] followers, [----] engagements

"At the EBMT-EHA 6th European CAR T-cell Meeting in Valencia Spain Dr. Edward J. Pearson of the Baylor Charles A. Sammons Cancer Center will present a case study on a patient from the dose escalation portion of the CB-010 ANTLER Phase [--] trial"
X Link 2024-02-13T15:30Z [----] followers, [----] engagements

"Preclinical data from CB-012 our allogeneic anti-CLL-1 CAR-T #celltherapy for the treatment of relapsed or refractory acute myeloid #leukemia will be presented at #AACR24 in San Diego. Read todays press release for full details: $CRBU @AACR https://bit.ly/4a26Oo3 https://bit.ly/4a26Oo3"
X Link 2024-03-05T21:34Z [----] followers, [----] engagements

"2023 was a year of significant clinical progress for Caribou. We look forward to continuing this momentum in [----]. Read our fourth quarter and full year [----] financial results here: #celltherapy #CRISPR $CRBU https://bit.ly/4a8SH0l https://bit.ly/4a8SH0l"
X Link 2024-03-11T20:09Z [----] followers, [----] engagements

"Our poster presentation from #AACR2024 featuring preclinical IND-enabling data from CB-012 our allogeneic anti-CLL-1 #CART cell therapy for the treatment of relapsed or refractory acute myeloid #leukemia is now available for viewing on our website: https://bit.ly/49q55bG https://bit.ly/49q55bG"
X Link 2024-04-09T20:55Z [----] followers, [----] engagements

"Today we announced two abstracts have been accepted at #ASCO24. The event will feature an update on initial clinical data from dose expansion in ANTLER Phase [--] trial. Read today's release for more details: $CRBU #CellTherapy #CRISPR https://bit.ly/3UvNzON https://bit.ly/3UvNzON"
X Link 2024-04-24T14:04Z [----] followers, [----] engagements

"In the past quarter Caribou has announced an IND clearance for lupus and has made progress across our clinical pipeline of allogeneic CAR-T cell therapies. Read more about it in our first quarter [----] financial results and business update: #CRISPR $CRBU https://bit.ly/44zJgW4 https://bit.ly/44zJgW4"
X Link 2024-05-07T20:16Z [----] followers, [----] engagements

"We are advancing four oncology and autoimmune disease clinical-stage programs through multiple clinical data milestones expected in [----] and [----]. Learn more about our progress in our Q2 [----] financial results here: $CRBU #CRISPR #CARTcelltherapy https://bit.ly/4dBvWUJ https://bit.ly/4dBvWUJ"
X Link 2024-08-06T20:07Z [----] followers, [----] engagements

"A wonderful piece by @Forbes on #CRISPR companies founded by former [--] under [--] winners featuring our president and CEO Rachel Haurwitz https://www.forbes.com/sites/michelatindera/2019/05/14/crispr-biotech-biosciences/#1e8c9d34300d https://www.forbes.com/sites/michelatindera/2019/05/14/crispr-biotech-biosciences/#1e8c9d34300d"
X Link 2019-05-15T14:53Z [----] followers, [--] engagements

"Thrilled to announce that the @FDA has cleared Caribous first IND for a CRISPR #genome-edited off-the-shelf allogeneic anti-CD19 CAR-T #celltherapy candidate for patients with relapsed/refractory B cell non-Hodgkin #lymphoma. Read more here: https://bit.ly/2F0cbvr https://bit.ly/2F0cbvr"
X Link 2020-09-08T14:20Z [----] followers, [---] engagements

"We are thrilled to announce a collaboration & multi-year license agreement for CAR-T cell products with @abbvie allowing for the potential to develop next-generation off-the-shelf cellular therapies to benefit a broader patient population. Read More: http://bit.ly/3cZYU4o http://bit.ly/3cZYU4o"
X Link 2021-02-10T16:14Z [----] followers, [--] engagements

"Were delighted to announce the completion of a $115M Series C financing to advance our next-generation #CRISPR technologies and allogenic cell therapies for #oncology. http://bit.ly/307B5QL http://bit.ly/307B5QL"
X Link 2021-03-03T18:01Z [----] followers, [--] engagements

"Thrilled to announce that the first patient has been dosed in our phase [--] clinical trial to evaluate a differentiated #CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy for patients with relapsed or refractory B cell non-Hodgkin lymphoma. Learn more: http://bwnews.pr/3e8ubSB http://bwnews.pr/3e8ubSB"
X Link 2021-07-12T12:50Z [----] followers, [--] engagements

"Today our CEO Rachel Haurwitz PhD is participating in the Cell & Gene Meeting on the Mesa discussing Caribous #chRDNA technology to enhance cell therapies for cancer. If attending check out the presentation to learn about our technology: #CGMesa21 http://cariboubio.com/technology/ http://cariboubio.com/technology/"
X Link 2021-10-12T13:53Z [----] followers, [--] engagements

"Our CEO Rachel Haurwitz PhD took part in @SFBusinessTimes Health + Biotech Forum: Future of Cell and Gene Therapy. Joined by Josh Lehrer of @GraphiteBio they shared their insights on the future growth of #biotech in the Bay Area.Learn about what we do: http://cariboubio.com/about http://cariboubio.com/about"
X Link 2021-10-21T22:31Z [----] followers, [--] engagements

"Thank you @LifeSciLeader for this wonderful feature on our CEO Rachel Haurwitz PhD and the exciting work that Caribou has done so far and whats to come. Check out the piece: https://www.lifescienceleader.com/doc/can-caribou-biosciences-top-0001 https://www.lifescienceleader.com/doc/can-caribou-biosciences-top-0001"
X Link 2022-03-03T18:14Z [----] followers, [--] engagements

"Excited to announce we are scheduled to share positive initial data for our ANTLER Phase [--] #clinicaltrial of CB-010 at #EHA2022 demonstrating a generally well tolerated safety profile & a 100% ORR & 80% CR in r/r B-NHL patients. Read more: https://bit.ly/3yrZzGG https://bit.ly/3yrZzGG"
X Link 2022-05-12T14:19Z [----] followers, [--] engagements

"We are excited to share additional data from our ANTLER Phase [--] #clinicaltrial today at #EHA2022 showing CB-010 as the 1st allogeneic CAR-T #celltherapy to achieve a 100% CR rate as best response for all [--] patients. To learn more watch our webcast here: https://bit.ly/38LLxFr https://bit.ly/38LLxFr"
X Link 2022-06-10T12:01Z [----] followers, [--] engagements

"Learn why our CEO Rachel Haurwitz PhD believes off-the-shelf cell therapy products should be the future of cancer therapeutics and how our next-generation CRISPR technology chRDNA can help make it a reality in this article by @VivRaper at @GENbio. #CRISPR #GeneEditing Critical to Delivering Off-the-Shelf #CellTherapy @CaribouBio has developed a gene-editing system that uses CRISPR hybrid RNA-DNA (chRDNA) guides to improve on traditional CRISPR Cas9 gene editing. Learn more: https://t.co/UCz00Q7lYA https://t.co/nx6dTqQsnv #CRISPR #GeneEditing Critical to Delivering Off-the-Shelf #CellTherapy"
X Link 2022-08-15T20:30Z [----] followers, [--] engagements

"Recognition of the Herds recent accomplishments continues with a shout-out to the CB-011 team for the incredible effort that went into achieving IND clearance for CB-011 our allogeneic CAR-T cell therapy for r/r #multiplemyeloma. Read more here: https://bit.ly/3XirT8h https://bit.ly/3XirT8h"
X Link 2023-01-25T19:42Z [----] followers, [----] engagements

"Preclinical data demonstrating potent antitumor activity in #multiplemyeloma with CB-011 will be shared in a poster presentation at #Tandem23 today at 5:45 p.m. ET. The poster is available on the Caribou website here: @ASTCT @CIBMTR http://bit.ly/3T9pLx7 http://bit.ly/3T9pLx7"
X Link 2023-02-16T16:05Z [----] followers, [----] engagements

"We are honored to have our #CEO Rachel Haurwitz PhD recognized by @SFBusinessTimes as one of the Bay Areas life science leaders. Read more here: https://bit.ly/3IY5mqY https://bit.ly/3IY5mqY"
X Link 2023-03-07T23:19Z [----] followers, [----] engagements

"Were pleased to share that our preclinical abstract for CB-012 our allogeneic anti-CLL-1 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia (AML) has been accepted for a poster presentation at #AACR2023. Read more here: https://bit.ly/3mR4xZV https://bit.ly/3mR4xZV"
X Link 2023-03-14T21:58Z [----] followers, [----] engagements

"The first patient has been dosed in the CaMMouflage Phase [--] trial evaluating CB-011 in patients with relapsed or refractory multiple #myeloma. CB-011 is second program from our allogeneic CAR-T cell therapy platform to advance into the clinic. $CRBU https://investor.cariboubio.com/news-releases/news-release-details/caribou-biosciences-announces-dosing-first-patient-cammouflage https://investor.cariboubio.com/news-releases/news-release-details/caribou-biosciences-announces-dosing-first-patient-cammouflage"
X Link 2023-03-29T12:10Z [----] followers, [----] engagements

"The ANTLER trial has advanced into dose expansion Dose expansion will include second-line patients with large B cell #lymphoma (LBCL) making CB-010 the first allogeneic CAR-T cell therapy to be evaluated in a clinical trial in second-line patients. $CRBU https://lnkd.in/gBVecexX https://lnkd.in/gBVecexX"
X Link 2023-03-29T12:10Z [----] followers, [----] engagements

"More good news CB-011 has received FastTrack designation from the #FDA. CB-011 is a clinical-stage off-the-shelf #CARTcell therapy for multiple #myeloma. $CRBU More details here: https://investor.cariboubio.com/news-releases/news-release-details/caribou-biosciences-announces-fda-granted-fast-track-designation https://investor.cariboubio.com/news-releases/news-release-details/caribou-biosciences-announces-fda-granted-fast-track-designation"
X Link 2023-04-04T12:09Z [----] followers, [----] engagements

"Today at the @AACR [----] Annual Meeting we presented preclinical data supporting evaluation of CB-012 our 3rd allogeneic CAR-T cell therapy program for the treatment of adult patients with r/r #AML #AACR2023 #cartcelltherapy #CRISPR https://investor.cariboubio.com/news-releases/news-release-details/caribou-biosciences-presents-new-preclinical-data-cb-012 https://investor.cariboubio.com/news-releases/news-release-details/caribou-biosciences-presents-new-preclinical-data-cb-012"
X Link 2023-04-17T17:32Z [----] followers, [----] engagements

"$CRBU has appointed world-renowned hematologist and CAR-T cell therapy pioneer Stephen Schuster to our scientific advisory board https://investor.cariboubio.com/news-releases/news-release-details/caribou-biosciences-announces-appointment-stephen-j-schuster-md https://investor.cariboubio.com/news-releases/news-release-details/caribou-biosciences-announces-appointment-stephen-j-schuster-md"
X Link 2023-05-08T13:02Z [----] followers, [----] engagements

"We are pleased to announce @pfizer has invested $25M in Caribou as part of the Pfizer Breakthrough Growth Initiative (PBGI) a program focused on funding promising clinical development programs of potential future strategic interest to Pfizer"
X Link 2023-07-06T12:05Z [----] followers, [----] engagements

"We are excited to announce that data from the [--] patients enrolled in dose escalation for the CB-010 ANTLER trial rival that of approved autologous #CARTcelltherapies. Read more here: https://bit.ly/3NUfP9x https://bit.ly/3NUfP9x"
X Link 2023-07-13T20:06Z [----] followers, [----] engagements

"Happy 11th birthday Caribou [----] has been an incredibly exciting year so far. Heres to many more as we develop transformative genome-edited allogeneic cell therapies for devastating human diseases"
X Link 2023-08-10T16:40Z [----] followers, [----] engagements

"We believe the future of CAR-T cell therapy is off-the-shelf and development of CB-010 would not be possible without outstanding clinical sites like @MCWCancerCenter and the courageous patients participating in the ANTLER trial. In July MCW #cancer researchers opened a phase [--] #ClinicalTrial to test CB-010 in adults with relapsed/refractory B cell non-Hodgkin #Lymphoma. The study is the first to test anoff-the-shelf CAR-T therapy in the second line setting: https://t.co/AHfebVqGNk #TherapyThursday https://t.co/eDwLTXY1ry In July MCW #cancer researchers opened a phase [--] #ClinicalTrial to test"
X Link 2023-08-14T16:04Z [----] followers, [----] engagements

"#ICYMI Caribou Biosciences recently announced positive clinical data from our phase [--] ANTLER trial. Learn more with last months @biospace piece about the announcement: https://www.biospace.com/article/caribou-scores-early-car-t-lymphoma-win-plans-125m-public-offering/ https://www.biospace.com/article/caribou-scores-early-car-t-lymphoma-win-plans-125m-public-offering/"
X Link 2023-08-22T15:00Z [----] followers, [----] engagements

"President and CEO of Caribou Biosciences Rachel Haurwitz PhD will participate on a panel tomorrow at the STAT Future Summit. Join Rachel at 1:35 pm ET to learn more about the future of CAR-T cell therapies. #STATFUTURE Join STAT at our Future Summit and watch our panel "The Future of CAR-T" Rachel Haurwitz David Chang and Lynelle Hoch speak with STAT's @adamfeuerstein Register: https://t.co/F9F7U1d8CC #STATFuture https://t.co/OBreqB9d9v Join STAT at our Future Summit and watch our panel "The Future of CAR-T" Rachel Haurwitz David Chang and Lynelle Hoch speak with STAT's @adamfeuerstein"
X Link 2023-09-05T15:37Z [----] followers, [----] engagements

"Dont miss our president and CEO Rachel Haurwitz discuss current CRISPR trends with Rodolphe Barrangouand Kevin Daviesat the @GENbio State of Biotech Summit tomorrow. Register for free using the link below. Join us TOMORROW for the virtual event of the year feat. Nobel Laureate Carolyn Bertozzi Daphne Zohar Rodolphe Barrangou & more. And the best part It's free @CarolynBertozzi @daphnezohar @CRISPRchef @Cytiva https://t.co/tKEMH2t4Gm https://t.co/KLzH6aooBd Join us TOMORROW for the virtual event of the year feat. Nobel Laureate Carolyn Bertozzi Daphne Zohar Rodolphe Barrangou & more. And the"
X Link 2023-09-12T15:58Z [----] followers, [----] engagements

"#WorldCancerResearchDay is a day to magnify the need for increased research resources & public awareness for those impacted by cancer. The Herd supports cancer research by working to advance potentially transformative allogeneic #CARTcelltherapies for patients with #BloodCancer"
X Link 2023-09-24T14:00Z [----] followers, [----] engagements

"Tomorrow at the Jefferies Cell and Genetic Medicine Summit join $CBRU president and CEO Rachel Haurwitz PhD for a fireside chat at 8:00 am ET. Head to our website for a link to the live webcast and replay of the discussion: https://investor.cariboubio.com/news-events/events https://investor.cariboubio.com/news-events/events"
X Link 2023-09-26T14:40Z [----] followers, [----] engagements

"We are proud to announce FDA clearance of the IND application for CB-012 our allogeneic anti-CLL-1 CAR-T cell therapy for r/r #AML. Read more about the CB-012 AMpLify Phase [--] trial here: #leukemia https://investor.cariboubio.com/news-releases/news-release-details/caribou-biosciences-announces-fda-clearance-ind-application-cb-0 https://investor.cariboubio.com/news-releases/news-release-details/caribou-biosciences-announces-fda-clearance-ind-application-cb-0"
X Link 2023-10-18T12:22Z [----] followers, [----] engagements

"We are excited to announce the appointment of Sundar Jagannath MD to our scientific advisory board. We welcome Dr. Jagannath and his insights as a renowned expert in the treatment of #multiplemyeloma. https://investor.cariboubio.com/news-releases/news-release-details/caribou-biosciences-announces-appointment-sundar-jagannath-md https://investor.cariboubio.com/news-releases/news-release-details/caribou-biosciences-announces-appointment-sundar-jagannath-md"
X Link 2023-11-06T17:42Z [----] followers, [---] engagements

"The Caribou team will be presenting at the 4th Annual #CRISPR [---] Conference next week in Boston Socorro Portella MD and Ashley Hammad RN will lead a workshop on Tuesday Nov. [--] at [--] pm ET and Enrique Zudaire PhD will present on Thursday Nov. [--] at 11:45 am ET. #CARTcell"
X Link 2023-11-22T18:36Z [----] followers, [----] engagements

"Caribou Biosciences SVP of translational sciences and therapeutic discovery Enrique Zudaire PhD will present clinical results from the CB-010 trial at the 4th Annual #CRISPR [---] Conference in Boston MA tomorrow at 11:45 am ET"
X Link 2023-11-29T15:13Z [----] followers, [----] engagements

"We are pleased to announce we have received feedback from the FDA following a Type B meeting for the CB-010 Phase [--] pivotal trial. Read todays press release for full details: https://bit.ly/3v065Vy https://bit.ly/3v065Vy"
X Link 2023-12-12T21:04Z [----] followers, [----] engagements

"Tune in on Thursday January [--] at 11:15 am PST for a company presentation by $CRBU president & CEO Rachel Haurwitz PhD at #JPM24. A link to the webcast is on the events section of our website: https://bit.ly/3E0bqxd https://bit.ly/3E0bqxd"
X Link 2023-12-21T19:40Z [----] followers, [----] engagements

"What a successful [----] Read todays press release for what is in store for Caribou in 2024: https://bit.ly/4aOhs3i https://bit.ly/4aOhs3i"
X Link 2024-01-07T16:18Z [----] followers, [----] engagements

"#WorldCancerDay is a day to bring increased awareness to cancer patients their families medical personnel and the caretakers who fight this disease together. The Herd is working to advance potentially transformative allogeneic #CARTcelltherapies: https://www.cariboubio.com/-pipeline/#trials https://www.cariboubio.com/-pipeline/#trials"
X Link 2024-02-04T15:00Z [----] followers, [----] engagements

"Today is International Day for Women and Girls in Science Caribou is proud to have some incredible women in the Herd serving as role models for future generations of female scientists RAs patent attorneys and regulatory specialists"
X Link 2024-02-11T15:30Z [----] followers, [---] engagements

"Prior to evaluating CB-011 in the ongoing CaMMouflage clinical trial the $CRBU team investigated the impact of our immune cloaking strategy in preclinical models. Read the full analysis here: #CRISPR https://bit.ly/4bzdD22 https://bit.ly/4bzdD22"
X Link 2024-02-12T16:00Z [----] followers, [----] engagements

"Mark your calendar for $CRBU presentations at upcoming investor conferences Read our press release for full details and webcast information: https://bit.ly/4bD6AFH https://bit.ly/4bD6AFH"
X Link 2024-02-16T17:00Z [----] followers, [---] engagements

".@Cancerdotnet estimates [-----] new cases of #MultipleMyeloma were diagnosed in [----] and the 5-year survival rate is approximately 58%. Caribou is dedicated to improving the current standard of care with a novel cell therapy approach. #MultipleMyelomaAwareness"
X Link 2024-03-14T15:00Z [----] followers, [----] engagements

"$CRBU is expanding clinical development of CB-010 into #autoimmunedisease. We have received IND clearance from the @US_FDA for CB-010 in lupus nephritis and extrarenal lupus. More details on the GALLOP Phase [--] trial here: #Lupus #autoimmune #CRISPR https://bit.ly/4am15dy https://bit.ly/4am15dy"
X Link 2024-04-04T20:02Z [----] followers, [----] engagements

"Caribou Biosciences will host an investor call this afternoon at 5:00 pm ET/ 2:00 pm PT to discuss our expansion into autoimmune disease and the GALLOP Phase [--] study design. A link to the webcast is available on the investor section of our website: $CRBU https://bit.ly/3E0bqxd https://bit.ly/3E0bqxd"
X Link 2024-04-04T20:05Z [----] followers, [----] engagements

"The Caribou team had a great time at #AACR2024 . Thanks to everyone who stopped by the poster. If you missed it be sure to check it out here: #AACR24 #AML https://www.cariboubio.com/file.cfm/11/docs/francica_aacrcb-012_poster_9_april_2024.pdf Our poster presentation from #AACR2024 featuring preclinical IND-enabling data from CB-012 our allogeneic anti-CLL-1 #CART cell therapy for the treatment of relapsed or refractory acute myeloid #leukemia is now available for viewing on our website: https://t.co/j1cUjD07uS https://t.co/2qKXXVaGGK"
X Link 2024-04-11T22:16Z [----] followers, [----] engagements

"Today is #AMLAwarenessDay. Caribou Biosciences is committed to improving treatment for #AML by developing an off-the-shelf CAR-T cell therapy for this devastating disease. Learn more about CB-012 here: #leukemia #CRISPR #CARTcelltherapy https://bit.ly/3TKg3Eb https://bit.ly/3TKg3Eb"
X Link 2024-04-21T13:00Z [----] followers, [----] engagements

"There are approximately [------] patients with systemic #lupus erythematosus (SLE) in the US. At Caribou were developing a #CARTcelltherapy that may improve treatment options for these types of devastating autoimmune diseases. #LupusAwarenessMonth #WorldLupusDay"
X Link 2024-05-10T13:43Z [----] followers, [----] engagements

"Our presentation from #ASGCT24 showing data on the use of Cas12a chRDNA for efficient genome editing in vivo is now available for viewing on our website: #CRISPR #geneediting https://bit.ly/3wvWEhy https://bit.ly/3wvWEhy"
X Link 2024-05-10T17:17Z [----] followers, [----] engagements

"We will be hosting a KOL discussion of CB-010 ANTLER Phase [--] clinical trial data at #ASCO24 this Sunday at 7:00 pm CT. Full details on the webcast and upcoming investor conferences here: #CRISPR #CARTcelltherapy $CRBU https://bit.ly/3x0zG2j https://bit.ly/3x0zG2j"
X Link 2024-05-30T20:09Z [----] followers, [----] engagements

"Join us Monday at #ASCO24 for two poster presentations sharing updated data from our ongoing ANTLER trial and the clinical trial design and objectives for our AMpLify trial. Poster session details here: #CARTcelltherapy #CRISPR #lymphoma #AML https://bit.ly/3K3Skt4 https://bit.ly/3K3Skt4"
X Link 2024-05-31T14:30Z [----] followers, [----] engagements

"Results from our ongoing ANTLER clinical trial indicate CB-010 with partial HLA matching has the potential to rival the efficacy and safety profile of approved autologous CAR-T cell therapies. Join us at 7pm CT for a live webcast and here for more details https://bit.ly/3R7f7rO https://bit.ly/3R7f7rO"
X Link 2024-06-02T23:08Z [----] followers, [----] engagements

"What advancements have been made to made to reduce off-targeting editing Caribous CSO Steve Kanner PhD provides insights on this panel discussion with @_CellandGene host Erin Harris: https://event.on24.com/wcc/r/4567517/FED38AAA6CBB0D4C1A17816A4E9F90FC https://event.on24.com/wcc/r/4567517/FED38AAA6CBB0D4C1A17816A4E9F90FC"
X Link 2024-06-25T17:11Z [----] followers, [----] engagements

"Happy Independence Day from the Caribou Biosciences team The Herd will be taking both the 4th and 5th off to spend time with family and friends. We wish you a restful holiday"
X Link 2024-07-04T13:30Z [----] followers, [----] engagements

"Today we announced the appointment of Terri Laufer MD to our scientific advisory board. Welcome to #theHerd Dr. Laufer #Lupus https://bit.ly/3S1cg42 https://bit.ly/3S1cg42"
X Link 2024-07-09T12:27Z [----] followers, [----] engagements

"Caribou Biosciences turns [--] Yesterday members of #TheHerd gathered to celebrate Caribous birthday and reminisce on the incredible discoveries and clinical progress over the years. #HappyBirthday #strongertogether"
X Link 2024-08-08T15:25Z [----] followers, [----] engagements

"Thank you to all who attended @CRISPRcon at @UCBerkeley http://www.crisprcon.org http://www.crisprcon.org"
X Link 2017-08-18T00:55Z [----] followers, [--] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing